Coloplast AS Class B

COLO B: XCSE (DNK)
View Stock Summary
Morningstar Rating for StocksFair ValueEconomic MoatCapital Allocation
V?#LOCK|%#v#LOCK|RVG@cxj

Coloplast Earnings: Decent Quarterly Results, but Braced for Medicare Cuts to Skin Substitutes

Coloplast posted fiscal first-quarter results showing 6% organic top-line growth and a 26% reported operating margin, but foreign exchange was a headwind. Shares fell by roughly 8%.

Sponsor Center